CervoMed

CervoMed is a public, Boston, MA-based company that focuses on advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. The company was originally launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry.

In August, 2023, EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIP’s development pipeline, but changing their name to CervoMed (CRVO).

For more information about the company and updates, please visit www.cervomed.com/ or follow them on Twitter at @Cervo_Med.

Overall, CervoMed's focus on CNS therapeutics and its recent merger with Diffusion Pharmaceuticals position it as an innovative player in the neurodegenerative disease treatment space. With a strong leadership team and promising pipeline, CervoMed presents an intriguing investment opportunity for venture capitalists looking to support advancements in neuropharmacology.